Connect your AI

CytomX Therapeutics CTMX Price / sales

Price / sales at other companies

PfizerPFE

2.5×+0.2×

AmgenAMGN

5.1×+0.2×

Janux TherapeuticsJANX

61.6×-109×

Allogene TherapeuticsALLO

20,300.1×+14,614×

ImmunomeIMNM

616.2×+563×

Arcus BiosciencesRCUS

11.5×+5.6×

Other financials

Income statement

Revenue$10.3M-79.9%

Operating income-$19.7M-187%

Net income-$18.2M-178%

EPS (diluted)-$0.10-137%

Balance sheet

Cash & equivalents$28.8M-39.4%

Total debt$2.9M-65.0%

Total equity$319.9M+1,177%

Total assets$359.4M+265%

Cash flow

Operating cash flow-$25.5M-21.4%

CapEx--100%

Free cash flow-$25.5M-20.7%

Valuation

Market cap$711.89M+94.8%

Enterprise value$685.92M+110%

Profitability

Operating margin-181.9%-206pp

Net margin-166.4%-195pp

FCF margin-225.6%-334pp

Returns & leverage

Return on equity-34.3%—

Debt / equity0×-0.3×

Current ratio10.4×+8.7×

Where this comes from

Calculated from CytomX Therapeutics’s reported figures.

market cap/total revenue=28.6×

Based on the most recent quarter.

The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about CytomX Therapeutics's price / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is CytomX Therapeutics's price / sales?: CytomX Therapeutics (CTMX) reported price / sales of 28.6× in Q1 2026.
How has CytomX Therapeutics's price / sales changed year-over-year?: CytomX Therapeutics's price / sales increased by 8183.6% year-over-year, from 0.3× to 28.6×.
What is the long-term trend for CytomX Therapeutics's price / sales?: Over 5 years (2020 to 2025), CytomX Therapeutics's price / sales has grown at a 8.7% compound annual growth rate (CAGR), from 6.2× to 9.5×.
What does price / sales mean?: Market capitalization at the quarter end divided by trailing-twelve-month revenue. The price the market pays for each dollar of sales.